SR10067 is primarily used as a selective agonist for the free fatty acid receptor 2 (FFA2), also known as GPR43. This makes it a valuable tool in research focused on metabolic regulation, inflammation, and immune responses. It is commonly applied in in vitro and in vivo studies to investigate the role of FFA2 in conditions such as type 2 diabetes, obesity, and inflammatory bowel disease. Due to its high selectivity and potency, SR10067 helps scientists dissect signaling pathways linked to short-chain fatty acids without activating related receptors. Its use enables the exploration of potential therapeutic targets in gut microbiota-related disorders and metabolic diseases.